Reboxetine Combination in Treatment-resistant Depression
to Selective Serotonin Reuptake Inhibitors
by
Lopez-Munoz F, Alamo C, Rubio G, Garcia-Garcia P, Pardo A.
1Pharmacology Department, Faculty of Medicine,
University of Alcala, Madrid, Spain.
Pharmacopsychiatry. 2007 Jan;40(1):14-9.

ABSTRACT

INTRODUCTION: Treatment-resistant depression is a relatively common clinical occurrence: between 60-70% of depressive patients fail to achieve total remission to the initial treatment with selective serotonin reuptake inhibitors (SSRI). METHODS: In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. Evaluation of antidepressant efficacy was carried out through the application of the Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Data were analyzed on an intent-to-treat basis, using the last-observation-carried-forward method. RESULTS: Mean score on the HDRS at baseline was 26.24+/-7.21, falling to 13.96+/-8.00 in week 12 (mean decrease of 46.79%; p<0.0001) The percentages of responders (HDRS total score >/=50%) and patients considered as benefiting from complete remission (HDRS score

Efficacy
Selectivity
Reboxetine
Venlafaxine
NARIs and SSRIs
Sexual side-effects
Noradrenaline and mood
Catecholamine depletion
Selectivity or multiplicity?
Reboxetine and the elderly
Noradrenaline reuptake inhibition
Sexual function: paroxeine v reboxetine

Refs
HOME
HedWeb
BLTC Research
Utopian Surgery?
Paradise-Engineering
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family